

# Anna Orsola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1496965/publications.pdf>

Version: 2024-02-01

28  
papers

1,332  
citations

471061

17  
h-index

552369

26  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1474  
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>Eur J Cancer</i> . 2016; 64:127-136. <i>European Journal of Cancer</i> , 2016, 68, 196-197.	1.3	0
2	Reply to K. Lu. <i>Journal of Clinical Oncology</i> , 2015, 33, 2716-2717.	0.8	0
3	Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. <i>Journal of Clinical Oncology</i> , 2015, 33, 643-650.	0.8	165
4	High-Risk Nonmuscle Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 227-236.	0.9	3
5	A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 310-319.	3.4	40
6	Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. <i>Current Opinion in Urology</i> , 2013, 23, 466-471.	0.9	19
7	Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. <i>Eur Urol</i> 2012;61:378-84. <i>European Urology</i> , 2012, 61, e53-e54.	0.9	2
8	Variant Forms of Bladder Cancer: Basic Considerations on Treatment Approaches. <i>Current Oncology Reports</i> , 2011, 13, 216-221.	1.8	48
9	Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. <i>BJU International</i> , 2010, 105, 202-207.	1.3	36
10	Preoperative Prediction of Pathologically Insignificant Prostate Cancer in Radical Prostatectomy Specimens: The Role of Prostate Volume and the Number of Positive Cores. <i>Urologia Internationalis</i> , 2010, 84, 153-158.	0.6	15
11	Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. <i>Eur Urol</i> 2008;54:303-14. <i>European Urology</i> , 2009, 55, e15-e16.	0.9	15
12	Alendronate decreases the fracture risk in patients with prostate cancer on androgen deprivation therapy and with severe osteopenia or osteoporosis. <i>BJU International</i> , 2009, 104, 1637-1640.	1.3	36
13	Is there a relationship between prostate volume and Gleason score?. <i>BJU International</i> , 2008, 102, 563-565.	1.3	8
14	Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer. <i>Urology</i> , 2007, 69, 500-504.	0.5	159
15	Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. <i>Journal of Urology</i> , 2007, 178, 1290-1295.	0.2	242
16	Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. <i>BJU International</i> , 2007, 99, 274-280.	1.3	56
17	The relationship between daily calcium intake and bone mineral density in men with prostate cancer. <i>BJU International</i> , 2007, 99, 812-816.	1.3	50
18	Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression. <i>Journal of Urology</i> , 2006, 175, 1679-1683.	0.2	90

#	ARTICLE	IF	CITATIONS
19	Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. <i>Anti-Cancer Drugs</i> , 2005, 16, 863-866.	0.7	13
20	Growth and stretch response of human exstrophy bladder smooth muscle cells: molecular evidence of normal intrinsic function. <i>BJU International</i> , 2005, 95, 144-148.	1.3	6
21	Correspondence Re: "Garat JM, de la Peña E, Caffaratti J, Villavicencio H. Prevention of Vesicoureteral Reflux at the Time of Complete Primary Repair of the Exstrophy-epispadias Complex. <i>Int Urol Nephrol</i> . 2004; 36: 211-216. <i>International Urology and Nephrology</i> , 2005, 37, 779-780.	0.6	2
22	Microencapsulation of Leydig Cells: A System for Testosterone Supplementation. <i>Endocrinology</i> , 2003, 144, 4975-4979.	1.4	69
23	Heparin-Binding Epidermal Growth Factor-Like Growth Factor Stimulates Androgen-Independent Prostate Tumor Growth and Antagonizes Androgen Receptor Function. <i>Endocrinology</i> , 2002, 143, 4599-4608.	1.4	55
24	The decision to undergo DNA or protein synthesis is determined by the degree of mechanical deformation in human bladder muscle cells. <i>Urology</i> , 2002, 59, 779-783.	0.5	26
25	A novel method for implantation of LNCaP prostate tumor cells under the renal capsule. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2001, 37, 360-362.	0.7	3
26	Controlled release of therapeutic agents: slow delivery and cell encapsulation. <i>World Journal of Urology</i> , 2000, 18, 80-83.	1.2	51
27	Heparin-Binding EGF-Like Growth Factor Is Up-Regulated in the Obstructed Kidney in a Cell- and Region-Specific Manner and Acts to Inhibit Apoptosis. <i>American Journal of Pathology</i> , 2000, 156, 889-898.	1.9	52
28	Cell-specific activation of the HB-EGF and ErbB1 genes by stretch in primary human bladder cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1999, 35, 371-375.	0.7	71